BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.
$7.63-0.78%
报价 2026-11-09
市值
$1.95B
EV
$2.44B
PE (TTM)
7.8x
预期 PE (FY2026)
–
52 周区间距高点 -31.3%
$6.24$11.11
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-09不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BCRXBioCryst Pharmaceuticals, Inc. | $1.95B | -0.8% | +15.8% | 97.7% | 7.8x | 7.0x | 5.6x | |
| SYRESpyre Therapeutics, Inc. | $10.06B | +4.9% | 0.0% | 0% | – | – | – | |
| PHVSPharvaris N.V. | $2.41B | +0.2% | – | 0% | – | – | – | |
| ZYMEZymeworks Inc. | $2.22B | +4.0% | – | 98.4% | – | – | – | |
| TRVITrevi Therapeutics, Inc. | $2.18B | +6.8% | – | 0% | – | – | – | |
| MAZEMaze Therapeutics, Inc. | $1.94B | +2.1% | +545.2% | 95.3% | – | – | – | |
| STOKStoke Therapeutics, Inc. | $1.8B | +4.4% | -81.2% | 98.9% | – | – | – | |
| NTLAIntellia Therapeutics, Inc. | $1.7B | +6.7% | -11.1% | -46.5% | – | – | – | |
| ARDXArdelyx, Inc. | $730.1M | +1.7% | +20.5% | 90.3% | – | – | – | |
| 同行中位数 | – | – | 0.0% | 45.1% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。